180 related articles for article (PubMed ID: 35414426)
1. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
[TBL] [Abstract][Full Text] [Related]
2. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
3. Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Chen L; Zhai Y; Wang Y; Fearon ER; Núñez G; Inohara N; Cho KR
Cancer Res; 2021 Jun; 81(12):3309-3318. PubMed ID: 33863776
[TBL] [Abstract][Full Text] [Related]
4. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
[TBL] [Abstract][Full Text] [Related]
5. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
[TBL] [Abstract][Full Text] [Related]
6. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
11. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
[TBL] [Abstract][Full Text] [Related]
12. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
13. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Huang D; Gaul DA; Nan H; Kim J; Fernández FM
J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
[TBL] [Abstract][Full Text] [Related]
14. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract][Full Text] [Related]
15. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
17. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin.
Lin SF; Gerry E; Shih IM
J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715
[TBL] [Abstract][Full Text] [Related]
18. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
19. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
[TBL] [Abstract][Full Text] [Related]
20. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer.
Stewart LM; Spilsbury K; Jordan S; Stewart C; Holman CDJ; Powell A; Reekie J; Cohen P
Cancer Epidemiol; 2018 Aug; 55():110-116. PubMed ID: 29935395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
